Mezzion PharmaLtd Past Earnings Performance
Past criteria checks 0/6
Mezzion PharmaLtd's earnings have been declining at an average annual rate of -0.04%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 8.3% per year.
Key information
-0.04%
Earnings growth rate
1.7%
EPS growth rate
Pharmaceuticals Industry Growth | 11.3% |
Revenue growth rate | 8.3% |
Return on equity | -16.1% |
Net Margin | -43.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
Jun 11Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking
Mar 04We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon
Feb 05Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain
Dec 14Revenue & Expenses Breakdown
How Mezzion PharmaLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 20,246 | -8,868 | 15,076 | 2,216 |
31 Mar 24 | 26,090 | -10,158 | 15,730 | 671 |
31 Dec 23 | 31,721 | -12,728 | 16,142 | 939 |
30 Sep 23 | 32,101 | -24,494 | 16,884 | 2,825 |
30 Jun 23 | 31,686 | -21,359 | 17,183 | 2,587 |
31 Mar 23 | 31,832 | -34,591 | 18,415 | 2,545 |
31 Dec 22 | 30,726 | -36,298 | 19,510 | 2,217 |
30 Sep 22 | 30,217 | -24,677 | 19,455 | 1,956 |
30 Jun 22 | 29,258 | -28,434 | 20,761 | 1,652 |
31 Mar 22 | 27,431 | -15,575 | 18,186 | 1,956 |
31 Dec 21 | 26,654 | -13,603 | 17,283 | 1,956 |
30 Sep 21 | 30,069 | -6,225 | 16,332 | -6,016 |
30 Jun 21 | 29,776 | -10,496 | 13,702 | -3,104 |
31 Mar 21 | 29,443 | -12,981 | 14,525 | -651 |
31 Dec 20 | 28,634 | -13,873 | 12,924 | 938 |
30 Sep 20 | 23,017 | -26,093 | 5,563 | 19,103 |
30 Jun 20 | 20,494 | -23,538 | 8,986 | 16,494 |
31 Mar 20 | 18,152 | -22,435 | 11,429 | 13,738 |
31 Dec 19 | 17,920 | -23,301 | 14,218 | 12,149 |
30 Sep 19 | 17,771 | -15,560 | 22,125 | 2,616 |
30 Jun 19 | 18,314 | -16,772 | 19,193 | 4,871 |
31 Mar 19 | 19,041 | -20,021 | 17,167 | 9,857 |
31 Dec 18 | 19,088 | -18,876 | 13,533 | 11,550 |
30 Sep 18 | 16,159 | -23,087 | 11,943 | 14,439 |
30 Jun 18 | 12,468 | -20,270 | 10,716 | 13,528 |
31 Mar 18 | 9,170 | -12,835 | 8,224 | 9,906 |
31 Dec 17 | 5,586 | -14,882 | 6,835 | 11,093 |
30 Sep 17 | 7,571 | -8,415 | 6,087 | 7,967 |
30 Jun 17 | 7,785 | -11,429 | 5,177 | 7,204 |
31 Mar 17 | 8,992 | -15,694 | 4,972 | 9,721 |
31 Dec 16 | 8,751 | -12,985 | 4,987 | 7,000 |
30 Sep 16 | 6,299 | -14,781 | 4,947 | 5,470 |
30 Jun 16 | 6,459 | -5,785 | 5,888 | 5,769 |
31 Mar 16 | 5,293 | -1,591 | 4,323 | 2,536 |
31 Dec 15 | 14,926 | 4,223 | 10,060 | 2,377 |
Quality Earnings: A140410 is currently unprofitable.
Growing Profit Margin: A140410 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A140410 is unprofitable, and losses have increased over the past 5 years at a rate of 0.04% per year.
Accelerating Growth: Unable to compare A140410's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A140410 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.5%).
Return on Equity
High ROE: A140410 has a negative Return on Equity (-16.1%), as it is currently unprofitable.